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Abstract Elucidation of the physiologically distinct subunits of troponin in 1973 greatly facilitated our understanding of cardiac
contraction. Although troponins are expressed in both skeletal and cardiac muscle, there are isoforms of troponin I/T
expressed selectively in the heart. By exploiting cardiac-restricted epitopes within these proteins, one of the most success-
ful diagnostic tests to date has been developed: cardiac troponin (cTn) assays. For the past decade, cTn has been regarded
as the gold-standard marker for acute myocardial necrosis: the pathological hallmark of acute myocardial infarction (AMI).
Whilst cTn is the cornerstone for ruling-out AMI in patients presenting with a suspected acute coronary syndrome (ACS),
elevated cTn is frequently observed in those without clinical signs indicative of AMI, often reflecting myocardial injury of
‘unknown origin’. cTn is commonly elevated in acute non-ACS conditions, as well as in chronic diseases. It is unclear why
these elevations occur; yet they cannot be ignored as cTn levels in chronically unwell patients are directly correlated to
prognosis. Paradoxically, improvements in assay sensitivity have meant more differential diagnoses have to be considered
due to decreased specificity, since cTn is now more easily detected in these non-ACS conditions. It is important to be
aware cTn is highly specific for myocardial injury, which could be attributable to a myriad of underlying causes, emphasizing
the notion that cTn is an organ-specific, not disease-specific biomarker. Furthermore, the ability to detect increased cTn
using high-sensitivity assays following extreme exercise is disconcerting. It has been suggested troponin release can occur
without cardiomyocyte necrosis, contradicting conventional dogma, emphasizing a need to understand the mechanisms of
such release. This review discusses basic troponin biology, the physiology behind its detection in serum, its use in the
diagnosis of AMI, and some key concepts and experimental evidence as to why cTn can be elevated in chronic diseases.
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1. Introduction
Intensive investigation into the mechanisms of striated muscle contraction
during the late 50 s and early 60 s led to evidence of a protein that
resembled tropomyosin and regulated the calcium sensitivity of the acto-
myosin contractile apparatus. This finding subsequently led to the discov-
ery of troponin by Ebashi and Kodama in 1965. Elucidation of the
physiologically distinct subunits of troponin by Greaser and Gergely1 in
1973 has facilitated a quantum-leap in our understanding of the molecular
physiology underpinning cardiac contraction. Consequent to their findings,
one of the most successful diagnostic investigations to date has been
developed: the cardiac troponin (cTn) assays. Whilst troponin is found in
all forms of striated muscle, troponin in the heart is distinguished by
regions of different amino acid sequences. Identifying the subtle dissimilar-
ities between cardiac and skeletal troponin enabled the raising of antibod-
ies against specific epitopes. These antibodies were exploited to develop
myocardial-specific assays. cTn assays have been regarded for the past
decade as the gold-standard biomarker for detecting acute myocardial
necrosis, the pathological hallmark of acute myocardial infarction (AMI).2
It is current routine practice for cTn assays to be run on any patient pre-
senting with a suspected acute coronary syndrome (ACS) to rule-in or
rule-out an AMI.3 However, compared to when the assays were first
developed, sensitivity and analytical performance have improved to such
an extent that cTn can be detected in the healthy population (Figure 1).
Over 50% of patients presenting with chest pain have cTn levels ele-
vated above the population-defined 99th percentile.4 Yet, in the absence
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of any confirmatory clinical signs or ancillary tests, such troponin eleva-
tion does not necessarily indicate an AMI. Troponin elevation without
AMI often reflects myocardial injury of unknown origin, leaving us with
the notion that the cTn assay is organ-specific, not disease-specific. Thus,
with the progression of time and assay technology, a multiplicity of con-
founding factors now have to be considered when interpreting cTn
results. Additionally, clinical studies have demonstrated that cTn can be
elevated in numerous chronic conditions.
In recent years, the literature suggests cTn can be released with rever-
sible cell injury in the absence of necrosis or cell death. This has been
prompted (and reinforced by), observations of increased cTn in clinical
situations whereby there is no obvious coronary syndrome, such as
extreme exercise. It is also unclear why cTn elevations are seen in
chronic diseases in the absence of ACS: yet such cTn elevations are
strongly predictive of survival. This review addresses the biology of tro-
ponin, the physiology behind its detection in serum, its clinical utilization
as a biomarker of AMI and myocardial injury, as well as the experimental
evidence behind cTn elevation in several chronic conditions.
2. Troponins
2.1 Background
The sarcomere is the fundamental contractile unit of the heart com-
prised of thick-filaments (myosin) and thin-filaments. The thin-filament is
a helix of two filamentous-actins (F-actin), which themselves are
polymers of globular-actin subunits (G-actin). The groove of the F-actin
helix contains tropomyosin to which troponin is attached (the
tropomyosin-troponin complex). Myofibrillar contraction is activated by
depolarization and then modulated by the interplay of Ca2þ with specific
regulatory sites on the contractile apparatus of striated muscle.5 This
regulatory site is the troponin complex, a tadpole-shaped heterotrimer
immobilized on the thin-filament, which acts in an allosteric manner to
regulate the Ca2þ-dependent interaction of actin and myosin filaments.6
Troponin was thought to be a single homogenous protein until the
late 60 s when it was fractionated into two distinct proteins by
Hartshorne and Mueller.7 Their findings raised the possibility of troponin
being a complex of multiple subunits, leading to the landmark study by
Greaser and Gergely1 in 1973 which introduced the troponin subunit
nomenclature still used today. Greaser and Gergely8 purified troponin
from rabbit skeletal muscle to reveal four major protein fractions using
SDS-PAGE. Reconstitution experiments were performed to find frac-
tions 2, 3, and 4 being constitutively required for normal troponin activ-
ity. The devised nomenclature was based on the functional properties
exhibited by these fractions. Fraction 2 (24 kDa) inhibited activity of
the Mg2þ-dependent actomyosin ATPase in the absence of Ca2þ, thus
named ‘I’ for inhibitory (TnI). TnI modulates the response to intracellular
Ca2þ by preventing actin-myosin interactions and cross-bridge forma-
tion in the absence of Ca2þ. Fraction 3 (37 kDa) bound to tropomyo-
sin thus named ’T’ for tropomyosin (TnT). TnT serves as the mechanical
link between tropomyosin (on the thin-filament) and the troponin com-
plex. Fraction 4 (20 kDa) was the Ca2þ-binding subunit and was named
‘C’ for calcium (TnC). TnC regulates activation of the thin-filament.9,10
2.2 Cardiac-specific isoforms of troponin
To be clinically useful, any biomarker intended for the detection of patho-
logical insults to the heart needs to be highly specific and sensitive. Since
both skeletal and cardiac muscle contract via a troponin-dependent
mechanism, the question arises as to how to differentiate myocardial
injury from skeletal muscle injury. The answer lies in the fact that there
are multiple isoforms of each troponin subunit which are encoded by dis-
tinct genes, some of which are expressed selectively in cardiac muscle.
Whilst TnI and TnT have distinct cardiac and skeletal isoforms, they share
a common isoform of TnC: the slow-twitch skeletal muscle isoform
(ssTnC) (Table 1). Thus in the healthy, fully developed heart, cardiac TnI
and cardiac TnT (cTnI and cTnT) and c/ssTnC are expressed in combina-
tion. There is developmentally regulated expression of certain TnI and
TnT isoforms which are downregulated postnatally (commonly referred
to as ‘foetal isoforms’).11 These foetal isoforms can be re-expressed post-
natally under certain pathological circumstances.
The ontology of cTnI is clear. During embryonic and foetal develop-
ment, ssTnI is expressed exclusively in the heart in lieu of cTnI.12 The
expression of this foetal isoform is downregulated and switched to cTnI
at 8–9 months postnatally.13 The case for cTnT is more complex.
cTnT is unique in that TNNT2 generates multiple alternatively spliced
transcripts encoding different isoforms. Four distinct cTnT isoforms are
generated via alternative splicing (designated cTnT1-4 numbered in order
of decreasing molecular size), where cTnT3 is the dominant isoform in
the normal adult heart.14 In addition to other proteins of the contractile
apparatus like myosin,15 reversion of troponin to foetal isoforms can
occur during disease states such as chronic heart failure. Reversion of
cTnI does not occur.13 cTnT2 is expressed to a significantly greater
extent compared to cTnT3 in failing hearts.
14 Since the cTnT assay
detects all cTnT isoforms, this has no impact on its clinical performance
in heart failure patients.16 However, it is worth noting that diseased skel-
etal muscle has been demonstrated to re-express foetal TnT which is
detected by cTnT assays, leading to false-positives.17
Normal cardiac function relies on the expression of all three troponin
subunits. This is exemplified by in vivo murine knockout models. cTnT-
knockout causes sarcomere disassembly and early embryonic lethality.18
Remarkably, knockout of cTnI in murine embryos has no effect on health
Figure 1 Illustration of the detection ranges of different cardiac tro-
ponin (cTn) assays. cTn can be detected in healthy individuals using
high-sensitivity assays, possibly due to physiological turnover of cardiac
myocytes (green line). Subsequent to an acute myocardial infarction
(AMI), there is a slight rise in cTn which may reflect either ischaemia-
induced release of the ‘early-release pool’ or micronecrosis (orange
line). After2–6 h there is a precipitous rise in cTn reflecting extensive
myocardial necrosis and degradation of myofibrillar cTn (red line).
With the evolution of assay technology, the 99th percentile value of
cTn which serves as a cut-off value for the diagnosis of AMI has been
accordingly reduced. Edited from Hochholzer et al.103 with permission.
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..before postnatal day 15, attributable to ssTnI compensating for the lack
of cTnI.19 However, the mice died on day-18 of acute heart failure sec-
ondary to TnI deficiency as ssTnI expression was downregulated. There
are no reports in the literature of cTnC-knockout studies (presumably it
would be lethal).
2.3 cTn is special
Since each troponin isoform is encoded by a separate gene, what makes
cTn special is fundamentally down to its protein structure. The amino
acid (AA) sequences for cTnI and cTnT were first identified in rabbits by
Grand et al.20 and Pearlstone et al.21 respectively. Identification of the AA
sequences for human cTnI and cTnT followed and were first reported
by Vallins et al.22 and Townsend et al.23 respectively. It was subsequently
identified that cTnI and cTnT sequences differed from their skeletal
counterparts. For example, cTnI contains 210 AA residues, 31 of which
could be utilized for assay development since they form an N-terminus
extension not found in skeletal troponin.22 We performed a protein
alignment using the Basic Local Alignment Search Tool (BLAST), to
show that human cTnI and ssTnI were 63% identical and 77% similar,
whilst cTnI and fsTnI are 57% identical and 76% similar (‘similar’ denotes
AAs that are chemically similar but not identical, i.e. conserved substitu-
tions) (NCBI accession numbers: TNNI1, J04760; TNNI2, L21715; TNNI3,
X54163). Since the cTnI assay uses highly specific antibodies, the magni-
tude of the absolute difference between skeletal and cardiac TnI is not
crucial– provided divergent epitopes are chosen carefully. This is evident
from the fact that both cTnI and cTnT assays currently in clinical use are
highly cardiac selective.
3. History of defining MI and cardiac
biomarkers
In the simplest terms, ‘myocardial infarction’ means death (necrosis) of
the myocardium due to inadequate oxygen supply. In the clinical context
however, ‘defining’ myocardial infarction is far more complex due to the
number of aspects by which myocardial necrosis can be assessed: histo-
pathologic, biochemical markers, electrocardiographic changes and
imaging.24 The development of cardiac biomarkers began in the 50 s (see
Collinson et al.25 for review). During the 60 s–70 s, creatine kinase (CK)
was shown to have clinical value in ruling-in/out an AMI. In tune with this,
a definition of AMI was presented in 1979 by the World Health
Organization,26 where the clinical diagnosis of an AMI was based on a
combination of indices: clinical symptoms (e.g. chest pain), ECG abnor-
malities (e.g. pathological Q waves), and serial cardiac enzymes (e.g. MB
isoenzyme of CK). However, the advent of more sensitive and
myocardial-selective biomarkers, combined with improved imaging tech-
niques, meant that very small amounts of myocardial injury and necrosis
could be detected–lesions that would not have been detected when
technology was less developed, necessitating redefinitions of MI.
Assays for cTnI were first described by Cummins et al.27 and subse-
quently for cTnT by Katus et al.28 In the clinical studies that followed,
meta-analyses subsequently demonstrated that cTn was better at pre-
dicting future major adverse cardiac events than CK-MB.25 Recognizing
the diagnostic superiority of cTn over traditional cardiac enzyme assays,
the National Academy of Clinical Biochemistry (NACB) subsequently
published in 1999 a consensus guideline for the clinical use of cTn
assays.29 A new definition of MI was presented by the Global MI Task
Force in 2000 incorporating the NACB report from 1998, stating that
either cTn, or if not available, CK-MB should be used in diagnosing an
AMI.24
In 2007, the troponin standard was adopted and the use of CK-MB in
the diagnosis of AMI was no longer recommended.30 Currently, the
Third Global MI Task Force defines an AMI as when there is evidence of
myocardial necrosis, in a clinical setting consistent with myocardial
ischaemia.2 In keeping with the previous definitions of MI, such evidence
incorporates clinical symptoms of ischaemia, ECG abnormalities and
imaging evidence. However, in contrast to the preceding definition, the
third definition now explicitly states that detection of a rise and/or fall
(i.e. a temporal or kinetic change) of cTn is paramount in making a diag-
nosis of AMI. The reason why the ‘rise and/or fall’ of cTn is emphasized is
attributable to the release kinetics of cTn (Section 4.3).
4. Detection of cTn in serum
4.1 The cTn assay
The differences in AA sequences permitted development of quantitative
assays for cTnI/T. Most cTn assays are non-competitive enzyme-linked
immunosorbent assays (ELISA) based on the sandwich principle, utilizing
the high specificity and affinity of antibodies.31 The assay is based on a
.................................................................... .................................................................... ..........................................................................
..............................................................................................................................................................................................................................
Table 1 Isoforms of the troponin subunits with their respective genes and expression sites
Troponin I (TnI) Troponin T (TnT) Troponin C (TnC)
Isoform (Gene) Expression site Isoform (Gene) Expression site Isoform (Gene) Expression site
Fast-skeletal
‘fsTnI’
(TNNI2)
Fast-twitch skeletal muscle Fast-skeletal
‘fsTnT’
(TNNT3)
Fast-twitch skeletal muscle Fast-skeletal
‘fsTnC’
(TNNC2)
Fast-twitch skeletal muscle
Slow-skeletal
‘ssTnI’
(TNNI1)
Slow-twitch skeletal muscle Slow-skeletal
‘ssTnT’
(TNNT1)
Slow-twitch skeletal muscle Slow-skeletal
‘ssTnC’ or ‘cTnC’
(TNNC1)
Slow-twitch skeletal muscle
and cardiac muscle
Cardiac
‘cTnI’
(TNNI3)
Cardiac muscle Cardiac
‘cTnT’
(TNNT2)
Cardiac muscle
The genes specified above have been described on the basis of molecular cloning in humans (OMIMVR , 1966–2015). They are expressed in a tissue-specific manner. There is no
unique cardiac isoform of TnC and ssTnC is found in both cardiac and skeletal muscle.11 For clarity, the literature often refers to ssTnC as cTnC. They are, however, analogous.
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capture antibody which binds to a specific epitope of cTn, and a detec-
tion antibody which binds to a separate epitope. The epitopes are often
closely spaced to prevent a proteolytic cleavage event diminishing sensi-
tivity. Further, the most stable regions of cTn are selected as epitopes;
regions that are not susceptible to cleavage or post-translational modifi-
cations, e.g. phosphorylation.16 The detection antibody is linked to a
signal-generating system to enable quantification. Signal amplification is
achieved by using an enzyme which can cleave multiple molecules of a
substrate over a given time-interval, or by using other detection method-
ologies such as gold microparticles32 and ruthenium.33
4.2 Multiple circulating forms of cTn
After the onset of myocardial ischaemia, cardiac myocyte death can
occur within 15 min, with histological evidence of necrosis appearing
within 4–6 h.24 cTn is released from the myocardium a few hours follow-
ing a period of ischaemia and is detectable in the venous circulation once
the interstitial fluid from the infarct zone has been cleared by the cardiac
lymphatics.34 cTnI/T are not only released in free-forms but also as non-
covalent ternary and binary complexes (Figure 2). Evidence from clinical
studies have shown that following AMI, cTnT primarily appears in blood
as a mixture of free-forms and the T:I:C ternary complex, whilst cTnI
appears predominantly as the I:C binary complex.35 In addition, all forms
of troponin are open to redox modifications and can exist as oxidized
and reduced forms.35 Though it is not completely clear exactly which
form of cTn is being detected during routine clinical practice, current
assays detect these different forms on a near-equimolar basis, so redox
changes are unlikely to affect clinical sensitivity.16
4.3 Subcellular localization and release
kinetics
Following an AMI, there is typically an initial peak of serum cTn followed
by a sustained elevation, for up to 14 days after symptom-onset (depend-
ing on the infarct size).36 This observation was made during early clinical
studies investigating the performance of cTn assays and at the time raised
some questions: (i) why are there differences in release profiles between
reperfusion, and non-reperfusion, following AMI; (ii) are there different
cellular distributions of cTn since it has a biphasic release profile.
Myocardial reperfusion is the restoration of coronary blood flow fol-
lowing an AMI via thrombolytic therapy, percutaneous coronary inter-
vention, or spontaneous thrombolysis. Reperfusion therapy is
established as the most effective strategy for reducing infarct size and
improving prognosis.37,38 An early clinical study by Katus et al.39 showed
that reperfusion following AMI results in both cTnT and CK-MB being
detected earlier and at greater magnitudes. Furthermore, the elevation
of cTnT is biphasic with reperfusion, but monophasic without. Generally,
the rate at which any protein is liberated depends upon its intracellular
location, molecular weight, and the local blood- and lymphatic-flow.
Since reperfusion restores blood flow to the infarct zone, one of the
explanations for the earlier detection of cTn in reperfused patients is
clearance/washout of the infarct zone. However, since Katus et al.39
observed the concentration of cTnT peaking at the same time as CK-MB
(localized in the cytosol), and since the release profile of cTnT was bipha-
sic, these observations cannot be accounted for by infarct-zone clear-
ance/washout alone.
Through studies employing human myocardium40 and a rat
Langendorff model,41 it was demonstrated that in fact, not all troponin
may be bound to the myofilament, which may account for the biphasic
release profile. This is demonstrated in a study by Remppis et al.41
whereby male Wistar rat hearts were homogenized and centrifuged.
The derived supernatant was used to measure the soluble cytosolic con-
centration of cTnT, whilst the resulting pellet was used to measure the
myofibrillar fraction of cTnT. Bleier et al.40 adopted a similar method but
using fresh human right atrial appendages, freshly excised from patients
with normal chamber pressures, to eliminate any bias.
It is thought that the serum concentration profile of cTn in reperfused
patients following an AMI is attributable to the findings from these early
studies, with release from a ‘cytosolic pool’ contributing to an initial peak
(Figure 2). Degradation of the contractile apparatus (‘structural pool’)
contributes the sustained elevation, which also reflects infarct size.16,42
This is substantiated by findings of cTn in the free-form (‘cytosolic pool’)
being detected shortly after the ischaemic insult, prior to detection of
the binary- and ternary-complexed forms of cTn.34 It should be noted
that whilst the release profile of cTnT is well-established as being bipha-
sic, for cTnI, it is recognized as being monophasic, lacking an initial early
peak.4 This has been suggested to be due to the cytosolic pool of cTnI
being smaller, although in practice there appears to be a similar early rise
of cTnI of a smaller magnitude.9
As an aside, the common usage of the term ‘cytosolic pool’ has been
challenged by several authors.16,43 cTnI/T has poor solubility in the
hydrophilic cytoplasm, thus it has been inferred that they may simply be
more loosely bound to the myofibril, as opposed to it being completely
isolated in the cytoplasm. Therefore, it is suggested the term ‘early-
release pool’ may be a more accurate term to describe the initial peak in
cTn.
4.4 Biochemical mechanisms of troponin
cleavage
Troponin is released from the myofibril due to proteolytic degradation
in the myocardium, both as intact proteins and as degradation prod-
ucts.16 So far, three myocardial enzymes have been implicated: (i) calpain
1, a Ca2þ-dependent cysteine protease44; (ii) caspase, a cysteine pro-
tease involved in mediating apoptosis; (iii) matrix metalloproteinase-2, a
zinc-dependent endopeptidase.45 These enzymes are also present in
blood and the complexes of cTnI (T:I:C and I:C complex) are susceptible
to degradation in the circulation.16 The N- and C-terminal regions of
cTnI are the most susceptible to proteolysis. The central region of cTnI
(residues 30-110) is the Ca2þ-dependent TnC binding domain and is the
most stable.9 As such, this is the region currently targeted by most cTnI
assays.34
5. Clinical uses of cTn
5.1 ACS
Acute coronary syndrome (ACS) is an umbrella term for ST-segment-
elevation MI (STEMI), non-ST-segment-elevation MI (NSTEMI) and
unstable angina, which share presenting symptoms but differ in underly-
ing pathology.3 Myocardial ischaemia is the first step in developing an MI
and occurs as a result of oxygen supply-demand mismatch2 or reduced
coronary flow.46 The pathophysiology underlying ACS is atherosclerotic
plaque rupture or erosion.47 This leads to progressive myocardial ischae-
mia which, if sustained, leads to infarction via three possible mechanisms:
(i) intraluminal platelet aggregation resulting in partial or complete vascu-
lar occlusion; (ii) release of platelet microaggregates which results in the
microembolization48 of small vessels to cause localized ischaemia and
infarction; (iii) progression of white thrombus formation to clotting cas-
cade activation which results in partial- or total-occlusion of the
4 K.C. Park et al.
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epicardial artery.47 The rise and/or fall in cTnI/T is used to distinguish an
AMI from unstable angina, whilst the ST-segment of the ECG is used to
distinguish between STEMIs and NSTEMIs.3
5.2 The 99th percentile
Early generations of the cTn assay were relatively insensitive. Troponin
detected by the early-generation assays were indicative of ‘substantial’
irreversible myocardial injury and carried diagnostic value.49 During the
past two decades however, assay sensitivity has improved to such an
extent, that even biological variation of cTn in the femtomolar range in a
healthy individual during a 4-h period can be detected.50 As cTn can be
detected in the normal population, the questions arises as to what con-
centration of cTn would have to be exceeded to constitute a ‘positive’
troponin. This dilemma is addressed by the 99th percentile, the popula-
tion based reference value determined from the normal population,
established to serve as the decision value by which an AMI can be con-
firmed or excluded (‘clinical decision value’; CDV) (Figure 3).51 It should
be noted however that the 99th percentile is not a panacea. It has been
challenging to determine a standardized cut-off, particularly for cTnI,
owing to the number of commercial assays that are available with differ-
ent characteristics and 99th percentiles. This is emphasized by a recent
prospective multi-centre study, whereby the approved CDVs for two
clinically available high-sensitivity (hs) assays (hs-cTnI and hs-cTnT), were
shown to be significantly inconsistent; one in five patients diagnosed as
having an AMI using hs-cTnT will receive a different diagnosis when hs-
cTnI is used.52 Further, the 99th percentile concentration is profoundly
influenced by the population demographics such as age and gender; cur-
rently, these factors have not been standardized.6 A report from 2012
highlights the magnitude of the effect that underlying demographics has
on the 99th percentile.51
For the reasons outlined above, patients presenting with chest pain
and a suspected ACS may have a ‘natural’ cTn concentration above the
99th percentile, which diminishes specificity. Similarly, because of the rel-
atively slow increase in serum cTn after myocardial injury, many patients
with an ultimate diagnosis of AMI may have a cTn concentration below
the 99th percentile at presentation, limiting sensitivity. To overcome
these limitations, the latest guidelines for rapid rule-out/rule-in advocate
decision cut-point concentrations well below and above the 99th per-
centile, thereby enhancing sensitivity and specificity. The drawback is
that the majority of patients lie in an intermediate ‘grey-zone’ between
these decision cut-points and need further investigation.3 Specificity is
further improved by a rise and/or fall in cTn (release kinetics) being a
major criterion for the diagnosis of AMI, as recommended by current
guidelines (Section 3 and 4.3).2
Figure 2 Structure of the cardiac troponin-tropomyosin complex and the forms of troponin released following myocardial necrosis. Whilst most car-
diac troponin (cTn) is bound to the myofibril, there is different subcellular localization of some cTn.2–4% and6–8% of cTnI and cTnT respectively exist
either unbound in the cytosol, or loosely bound to the sarcomere. Following myocardial ischaemia, the ensuing necrosis of cardiac myocytes results in differ-
ent forms of cTn being detectable in serum. After ischaemic insult, the free forms of cTnI and cTnT from the cytosol are soon detected in serum prior to
detection of the complexed forms. There are several complexed forms that exist: non-covalent ternary complexed cTnT-I-C (T:I:C complex) and binary
complexed cTnI-T (I:T complex). Edited from Gaze and Collinson34 with permission.
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5.3 cTn is organ-specific, not disease-
specific
The high myocardial specificity and clinical sensitivity of cTnI/T for myo-
cardial injury is well accepted.2 However, claiming specificity for any par-
ticular disease is untenable. It is important to acknowledge that neither
cTnI nor cTnT are exclusively released due to MI, and that they can be
released both as a result of ischaemic, non-ischaemic and extra-cardiac
conditions.42 This notion is of particular relevance to emergency depart-
ment (ED) clinicians where20% of patients attending the ED have ele-
vated cTn, although the majority of these patients do not have ACS.4
There are a large (and ever increasing) number of acute and chronic con-
ditions where elevated cTn can be detected in the absence of ACS or
other obvious causes of significant ischaemic myocardial necrosis.4,53,54
The elevation of cTn in the absence of ACS is likely to be multifactorial,
including myocardial ischaemia, increased wall tension and ventricular
strain, direct myocyte trauma, excess catecholamines, and possibly
impaired renal clearance.4
6. cTn as biomarkers of chronic
disease
There have been no prospective studies to date altering patient treat-
ment to determine whether it has an effect on troponin release. As such,
controversy remains as to the precise mechanisms by which cTn can be
elevated in chronic disease states including chronic heart failure (CHF),
diabetes, pulmonary arterial hypertension, stable coronary artery disease
(CAD), and chronic kidney disease (CKD).4 Our current understanding
on how cTn is elevated in chronic conditions is based on clinical trials
and animal models.
Indeed, cTn measured using both the conventional55 and hs-cTn4
assays have been shown to have prognostic value, suggesting cTn is a
good ‘barometer of risk’ in chronically unwell patients. Notably, several
studies have demonstrated that cTn increases, even within the reference
range of healthy individuals, is predictive of risk.56 Elevated baseline hs-
cTnT in low-risk, normotensive, ambulatory individuals has been shown
to be predictive of developing clinical hypertension.57 Furthermore, tem-
poral increases in hs-cTnT over a 6-year period have been associated
with subsequent CAD, HF (both reduced and preserved ejection frac-
tion subtypes), and death.58
There is an extensive literature on cTn in the context of CHF, where
troponin values above the 99th percentile are associated with a worse
prognosis.59,60 Hs-cTnT levels are higher in patients with higher NYHA
classes, and strongly associated with clinical outcome and all-cause mor-
tality.61 Comparable conclusions were made on hs-cTnT levels and out-
come in CHF by meta-analysis.62 An interesting observation by Masson
et al.62 was that outcome tended to improve in CHF patients with
decreasing hs-cTnT levels over time.
Additionally, a recent clinical study has made some important obser-
vations. 3318 male participants with moderate hypercholesterolaemia
were randomized to receive placebo or pravastatin with hs-cTnI meas-
ured at baseline and at 1 year. cTnI concentration was reduced by 13%
with statin therapy, and reductions in troponin concentrations were
associated with better outcome (independent of low-density lipoprotein
cholesterol lowering).63
Importantly, troponin elevations are not only relevant in individuals
with cardiovascular diseases, but are important in those with extra-
cardiac diseases. Sandoval et al.64 reported that serial increases in hs-cTn
levels over a 3-month period in CKD patients undergoing haemodialysis
was related to a greater risk of all-cause mortality.64 The conclusions
made by Sandoval et al.64 were based on relative change values as
opposed to absolute change values, which accounts for the biomarker’s
biological variability.65 Currently, it is unclear whether absolute, or rela-
tive changes in troponin values are better for clinical practice.65
There are a number of chronic diseases in which elevated troponin
has been documented.53,54,59 The possible mechanisms by which cTn
can be released are illustrated in Figure 4. Examples include diabetes mel-
litus, hypotension and stroke.42 In the case of stroke, although cTn eleva-
tions have only been reported under ‘acute’ situations (e.g. immediately
following subarachnoid haemorrhage; SAH), the main risk factor for
mortality long-term in stroke survivors are manifestations of cardiovas-
cular disease (e.g. CAD).66 Excessive catecholamine release following
SAH (demonstrated in both humans67 and the canine68) may result from
cardiomyocyte death through increased myocardial demand.
Understanding these mechanisms remains a key issue and is high-
lighted by a large retrospective study. In a study of all patients admitted
to US Veterans Affairs hospitals during 2006, only 42.8% of the patients
who tested positive for cTn had a primary diagnosis of ACS.69 CHF and
CAD were the most common diagnoses amongst these patients, but
renal conditions were also a frequent diagnosis amid a range of other pri-
mary diagnoses of extra-cardiac origin. Indeed, the idea that troponin
can be detected under clinical circumstances, in which there is no appa-
rent myocardial ischaemia, is not new.55 What is not highlighted in Figure
4 are the pathobiological mechanisms by which these cTn elevations can
Figure 3 The 99th percentile diagnostic cut-off for cardiac tropo-
nin (cTn) assays. A hypothetical case of an acute coronary syndrome is
shown to illustrate the evolution of cTn assay precision and sensitivity.
The diagnostic cut-off for cTnI assays in 1995 was >_ 1.5 ng/mL, in 2003
0.10 ng/mL and in 2007 > 0.04 ng/mL. The increasing sensitivity of the
assays meant that very small concentrations of cTn could be detected,
thus the 99th percentile decision limit had to be lowered. The 99th per-
centile quantitatively represents a value at which 1 person in 100 will
have a false positive result.6 Any concentration of cTn detected within
the 99th percentile decision limit suggests a ‘normal’ result. Any con-
centration value which falls outside this decision limit indicates a ‘posi-
tive’ cTn and substantiates a possible AMI. Edited from Mahajan and
Jarolim87 with permission.
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potentially occur. Broadly, there are six major potential mechanisms:
myocyte necrosis, apoptosis, normal myocyte turnover, cellular release
of proteolytic degradation products, increased cell wall permeability, and
the formation and release of membranous blebs.70 Some of these mech-
anisms are discussed in the following sections.
To detect any biomarker, there must be either increased release of
that marker, or reduced clearance from the circulation. It has been pro-
posed that cTn detected in patients with chronic renal dysfunction is a
result of reduced renal clearance. However, the evidence for this is
debated and the notion of reduced clearance remains controversial
(Section 6.3). The lines of evidence to date strongly support the case that
we are detecting troponin that is released as opposed to that not being
cleared. We will discuss key evidence and possible mechanisms by which
cTn had been reported to be elevated in a subset of chronic conditions.
6.1 Myocardial ischaemia
During initial assay development, it was established that troponin is
released exclusively upon cardiac myocyte necrosis with membrane
disruption, due to irreversible cell damage.27,28 This was validated by an
experimental study by Fishbein et al.71 The authors performed immuno-
histochemistry with antibodies against cTnI and cTnT, on archival,
formalin-fixed, paraffin-embedded myocardium from a large number of
experimental animals that had undergone different durations of coro-
nary occlusion with/without reperfusion. Their results showed that cTnI/
T can be released as early as 30 min of coronary occlusion, preceding his-
tologic evidence of necrosis. The conclusion was that all loss of cTnI/T
from myocardium was necrotic.72
However, it was postulated that myocardial ischaemia, without
necrosis, can result in the release of troponin.73 Clinical studies have
reported increased cTn without any obvious ischaemic heart disease,74
and also, after extreme exercise75 (although the intensity and modality
of exercise undertaken may also be a determinant in cTn release).76,77
As reported by several authors,4,70,75 the suggestion has been made that
troponin can be released ‘without irreversible necrosis’ or with ‘reversi-
ble cell damage’, leading to debate as to whether myocyte necrosis (or
even myocyte death) is necessary for troponin release.75 Despite a num-
ber of interesting postulates, currently accepted experimental evidence
Figure 4 Presumed mechanisms for elevated cardiac troponin (cTn) in chronic diseases. Elevated cTn has been documented in the conditions listed.
AF, atrial fibrillation; CAD, coronary artery disease; CHF, chronic heart failure; CKD, chronic kidney disease; ESRD, end-stage renal disease; LV, left ventricle;
MVO2, myocardial oxygen consumption; PAH, pulmonary arterial hypertension; RAAS, renin-angiotensin-aldosterone system; RV, right ventricle. Adapted
from Jeremias and Gibson.53
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supports that the release, and detection of cTn, is due to irreversible cell
death.33 Some of the experimental evidence which has led to the possi-
ble view that cTn may be detected with chronic ischaemia alone, without
necrosis, is discussed below.
Stable CAD has been implicated as a condition associated with ele-
vated cTn and it is thought that repeated, short-lived episodes of
ischaemia over a ‘chronic’ time-course, could be part of its aetiology.4
However, there are no experimental studies that have aimed to
directly address this. Therefore, to establish how CAD may result in
elevated cTn, we are restricted to causal relationships established
from clinical studies and to inferring mechanisms from experimental
studies using myocardial ischaemia. Feng et al.78 showed that reduced
flow in the left anterior descending artery (LAD; as a mimic of severe
coronary artery stenosis; 36% reduction in flow) in an in vivo swine
model resulted in elevation of cTnI, CK-MB and myoglobin. Hearts
were subsequently excised and histologically examined (triphenylte-
trazolium chloride staining) to assess whether infarction was evident.
Pigs that did not develop necrosis (assessed by histology) still
released cTnI. The authors concluded that increased levels of cTnI
can be detected after reversible and irreversible myocardial ischae-
mic injury.
Elevated cTn in stable CAD may be attributed to enhanced proteo-
lytic degradation of myofibrillar troponin. Reduced Ca2þ extrusion by
the Na/Ca exchanger, with concomitant reduced Ca2þ uptake by the
sarcoplasmic reticulum, may produce local elevations of the concentra-
tion of intracellular Ca2þ during ischaemia.79 With repeated episodes of
short-lived ischaemia (i.e. CAD), the activity of the Ca2þ-dependent
protease calpain could be increased, leading to chronic proteolytic deg-
radation of myofibrillar cTn. However, one of the determinants which
would confirm this mechanism would be whether there is increased
intracellular Ca2þ during episodic bouts of ischaemia over chronic peri-
ods. This has not yet been studied. Indeed, in agreement with this
hypothesis, it may be possible that proteolysis creates small fragments of
troponin that can pass through the cellular membrane with normal
membrane integrity (i.e. cTn release without cell death).70
Another pathobiological mechanism by which intact troponin may be
released during ischaemia without necrosis is the formation and release
of membranous blebs.70 Blebs are spherical protrusions of the plasma
membrane. Their development is driven by increases in cytoplasmic
(intracellular) hydrostatic pressure.80 Blebbing is considered to be a key
characteristic of the execution phase of apoptosis, but strikingly it is also
well known that blebbing is involved in key physiological processes of
healthy cells such as during cytokinesis.80,81 It has been proposed by
Hickman et al.82 that ischaemic cardiomyocytes form and release blebs
containing the unbound, cytosolic faction, or the loosely-bound myofi-
brillar faction, of cTn. It may be entirely possible that cardiomyocytes
form and release blebs. However, although well established in hepato-
cytes, the evidence for blebbing in cardiomyocytes has not been
substantiated.
A recent experimental study using an in vivo swine model demon-
strated cTnI release following 10 min of coronary occlusion.83 Although
histological evidence of necrosis was absent after the brief period of
ischaemia, positive caspase staining (Section 4.4) and terminal deoxynu-
cleotidyl transferase-mediated dUTP nick-end labelling (TUNEL) sug-
gested myocytes underwent irreversible injury from apoptosis.83 The
precise mechanism of cell death is debateable, since apoptotic bodies, in
principle, retain membrane integrity. Although a possibility may be that
cardiomyocyte apoptosis transitioned to secondary necrosis,84 alterna-
tive mechanisms could exist.85
Collectively, it is important these concepts be interpreted carefully.
Indeed, there is a spectrum of injury with myocardial ischaemia/reperfu-
sion, ranging from reversible damage with mild ischaemia (where there is
functional recovery), to irreversible injury with severe ischaemia.86
However, although there may be no overt evidence of cell death at the
organ level, it is highly unlikely even a small population of myocytes have
not died.70 Considering that the analytical sensitivity of conventional cTn
assays are in the picomolar range, whilst hs-cTn assays can detect cTn in
the femtomolar range,87 what is more likely the case is that there is death
of cardiomyocytes, but at a level which cannot be detected by any alter-
native analytical method (e.g. triphenyltetrazolium chloride, lactate elu-
tion). A new experimental study substantiates this idea, whereby hs-cTn
assays were able to detect serum elevations of troponin from necrosis
of a few milligrams of myocardium: an amount of irreversible injury
beyond the resolution of any imaging technique.88
6.2 Myocardial strain
The idea of ‘myocardial strain’ describes the release of cTn due to cardi-
omyocyte injury resulting from mechanical deformation or physiological
stress.53 During CHF, there is ventricular volume and pressure overload.
This was hypothesized by Jeremias and Gibson53 to cause excessive wall
tension and direct myofibrillar damage, resulting in cardiomyocyte death,
and thus troponin release in the absence of ischaemia (myocardial strain
theory). This is supported by both experimental studies and clinical
observations.
Cheng et al.89 demonstrated in an in vitro study, stretch-mediated
apoptosis of papillary muscle myocytes. Their data showed excessive
stretch can result in apoptosis, which in the context of our discussion,
may result in cTn release. Indeed, detection of cTn would be dependent
on whether apoptotic cells lose membrane integrity.84
In a clinical study by Logeart et al.,90 left-ventricular (LV) assessment
was performed in conjunction with measuring cTnI and B-type natriu-
retic peptide (BNP) concentrations (a marker of ventricular wall strain)
in 71 CHF patients. Patients with CAD and atherosclerotic abnormalities
were excluded. They made the following observations: (i) there is a posi-
tive correlation between cTnI concentration and both LV wall thickness
and BNP levels; (ii) cTnI release occurs in patients without ischaemic dis-
ease. Combining these findings and those of previous studies where BNP
levels and LV filling pressure were positively correlated, the authors
postulated that the release of cTnI could be due to significantly high LV
filling pressures, causing stretch-mediated cardiomyocyte death. The
authors also confirmed by imaging that these patients had increased wall
thickness, which may have resulted in endocardial ischaemia and cardio-
myocyte death.
Increased preload (diastolic wall stress) is a key feature of the failing
heart. Both clinical and experimental studies suggest it may initiate tropo-
nin release. In an elegant clinical study, Takashio et al.91 measured the
Dhs-cTnT level between the aortic root and the coronary sinus, in 76
CHF patients undergoing cardiac catheterization. This approach was
taken to exclude alternative clinical causes of troponin release (e.g.
CAD). The aetiology of HF in these patients was non-ischaemic (e.g.
cardiomyopathy). The authors found that Dhs-cTnT was higher in HF
patients vs. non-HF patients (n= 28), and that Dhs-cTnT was significantly
correlated to LV end-diastolic pressure (a primary determinant of
preload).
In Langendorff-perfused rat hearts, high preload resulted in greater
degradation of cTnI: an effect attenuated by adding calpeptin (a calpain
inhibitor). As a result, Feng et al.92 demonstrated that increased preload
may result in increased myocyte Ca2þ-entry secondary to mechanical
8 K.C. Park et al.
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strain independent of ischaemia, thus leading to activation of l-calpains
and calpain-mediated cTnI proteolysis. As an aside, results from this
study have been used to theorize the release of cTn during acute decom-
pensated HF.4 It should be noted however, results from Feng et al.92
have been interpreted by some investigators as the release of troponin
by live, viable cardiomyocytes which exhibit increased sarcolemmal
permeability, thus enabling troponin ‘leakage’.70 In other words, no cell
death. Furthermore, it has been suggested that intact cTn may be
released by live, viable myocytes, via stretch-mediated integrin stimula-
tion. This has been reported in cultured neonatal rat cardiomyocytes93
where peptide-mediated integrin agonism was shown to result in
increased cTnI release in the absence of necrosis [assessed by LDH
assays and nuclear propidium iodide staining].
Jaffe and Wu75 identify experimental issues with interpreting the find-
ings from Hessel et al.93 (e.g. the use of LDH as a biomarker of cell
death). However, these issues aside, there is some simple physiology to
consider when thinking about the idea of increased membrane perme-
ability. Troponins are large molecular weight proteins (cTnI 24 kDa;
cTnT37 kDa), and there is currently, no specialized biological process
(e.g. exocytosis) that has been validated for the physiological, or patho-
logical release of these large proteins. Moreover, should there be an
increase in cardiomyocyte membrane permeability, to the extent at
which free troponin from the cytosol or loosely-bound myofibrillar tro-
ponin can freely leave the myocyte, the possibility cannot be ignored
that Ca2þ will leak into the myocyte following a transmembrane concen-
tration gradient (causing hypercontracture and Ca2þ-mediated cell death).
It is clear that at present, as highlighted by Jaffe and Wu,75 although
necrosis is not a requisite for cTn release, cell death in any shape or form
can result in its release (e.g. autophagy, apoptosis, necroptosis).94
Altogether, the mechanistic and clinical studies discussed provide some
compelling data indicating that cTn can be released due to cell death
caused by ‘strain’–most likely via proteolytic and apoptotic mechanisms.
6.3 Chronic kidney disease
Elevated cTnI and cTnT are frequently observed in patients with CKD.95
It has been shown in a meta-analysis that cTnT in end-stage renal disease
(ESRD) carries prognostic significance, with elevated cTnT being strongly
associated with mortality.96 Increases in hs-cTnI levels have been dem-
onstrated to be predictive for sudden cardiac death: a frequent and
major cause of mortality in CKD/ESRD patients.64 However, with limited
and often contradictory experimental data available, the mechanism(s)
by which cTn is elevated in CKD is poorly understood.97 Data from clini-
cal studies strongly suggest direct cardiac damage in the absence of acute
myocardial ischaemia to be the mechanism of increased cTn release.95
With a high incidence of CAD in CKD patients98 such damage may be
attributable to clinically-silent micro-infarcts (i.e. subclinical cardiac dam-
age).99 LV hypertrophy and raised LV preload are common in patients
with ESRD, which could lead to increased cTn release as a result of myo-
cardial strain and myocardial O2 supply-demand mismatch.
100 CKD
patients are also typically hypertensive.98 Thus myocardial strain conse-
quent to increased LV afterload could present another mechanism by
which cTn is elevated.
Reaching a consensus on the mechanisms by which cTn is elevated in
CKD and ESRD has been complicated by the multiple assay platforms
available, but also by the fact that the stage of renal disease is not
standardized across studies. Most of the evidence available has been on
ESRD patients undergoing regular haemodialysis. In such patients, cTnT
is more frequently elevated than cTnI.101 An explanation for this obser-
vation may be that cTnI, but not cTnT, adheres to polysulphone dialyser
membranes during haemodialysis.102 Indeed, polysulphone membranes
are not the only types in current clinical use, but it does raise the inter-
esting question that cTnI may be adhering to other types of synthetic
dialysis membrane. The mechanisms by which cTn is detected in CKD
and ESRD patients remains highly controversial.
7. Conclusions
Originally the rationale behind the cTn assay was relatively simple: myo-
cardial necrosis leads to membrane disruption causing troponin release
which is detected in serum. The troponins have been used to diagnose
acute myocardial injury and such use has become engrained in the
Universal Definition of Acute Myocardial Infarction. Today however,
with the evolving sensitivity of cTn assays, it is clear cTn is detectable in
everyone and becomes elevated above the 99th percentile in stable
chronic conditions. These features of the high-sensitivity assays have
made the interpretation of cTn results more complex.
In recent years, the concept that troponin can be released with rever-
sible cell injury, without necrosis, or even cell death, has been repeatedly
suggested. In part, this is due to increased cTn being observed in several
clinical situations whereby there are no obvious signs of overt cardiac
disease, and in particular with the consistent finding of increased hs-cTn
following extreme exercise. However, it is emphasized that current evi-
dence reinforces the view that cTn is only released from cardiomyocytes
upon irreversible cell death (whether it be by necrosis or apoptosis etc.).
Future research needs to embrace the high-sensitivity of the latest
assays to expand their use in personalizing medical therapy. In particular,
we believe that concentrations below and around the 99th percentile
could be used to select higher risk patients for future randomized trials in
HF and prevention of vascular events. Another under explored area is
understanding if additional information, over and above concentration, is
gained by measurement of post-translational modifications in circulating
cTnI and cTnT. Since varied forms of cTn can be detected in serum fol-
lowing AMI (e.g. following proteolytic cleavage, post-translational modifi-
cations etc.), the future assays may not just feature enhanced analytic
sensitivity, but also the ability to detect different forms of cTn released
during different ‘stages‘of ischaemia–as identified by Wu et al.35 and pro-
posed by McDonough and Van Eyk.45 Whatever the direction of evolu-
tion, one thing is certain: biomarkers of myocardial injury are here to stay.
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